The risk or severity of adverse effects can be increased when Telmisartan is combined with Ramipril. Phentolamine may increase the hypotensive activities of Telmisartan. Telmisartan may increase the hypotensive activities of Deserpidine. The risk or severity of adverse effects can be increased when Bupivacaine is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Rescinnamine. The risk or severity of adverse effects can be increased when Telmisartan is combined with Aceclofenac. The risk or severity of adverse effects can be increased when Valsartan is combined with Telmisartan. The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Tolmetin. The risk or severity of adverse effects can be increased when Telmisartan is combined with Diflunisal. Telmisartan may increase the hyperkalemic activities of Cyclosporine. The risk or severity of adverse effects can be increased when Telmisartan is combined with Magnesium salicylate. Barbital may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Acetylsalicylic acid. The risk or severity of adverse effects can be increased when Telmisartan is combined with Bucillamine. The serum concentration of Ouabain can be increased when it is combined with Telmisartan. Latanoprost may increase the hypotensive activities of Telmisartan. Molsidomine may increase the hypotensive activities of Telmisartan. Benmoxin may increase the hypotensive activities of Telmisartan. The serum concentration of Ledipasvir can be increased when it is combined with Telmisartan. Telmisartan may increase the hypotensive activities of Obinutuzumab. Dihydralazine may increase the hypotensive activities of Telmisartan. The serum concentration of Doxorubicin can be increased when it is combined with Telmisartan. Minaprine may increase the hypotensive activities of Telmisartan. The serum concentration of Afatinib can be increased when it is combined with Telmisartan. Telmisartan may increase the hypotensive activities of Risperidone. The risk or severity of adverse effects can be increased when Sacubitril is combined with Telmisartan. The serum concentration of Topotecan can be increased when it is combined with Telmisartan. Trimazosin may increase the hypotensive activities of Telmisartan. Enoxaparin may increase the hyperkalemic activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Guanfacine. Alprenolol may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Aldesleukin is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Ibuprofen. Diazoxide may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Furosemide is combined with Telmisartan. The risk or severity of adverse effects can be increased when Propranolol is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Benoxaprofen. The risk or severity of adverse effects can be increased when Telmisartan is combined with Etoricoxib. The risk or severity of adverse effects can be increased when Telmisartan is combined with Imidapril. The risk or severity of adverse effects can be increased when Telmisartan is combined with Flurbiprofen. The risk or severity of adverse effects can be increased when Tretinoin is combined with Telmisartan. The risk or severity of adverse effects can be increased when Amiodarone is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Captopril. The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Telmisartan. Methylphenobarbital may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Carvedilol. The risk or severity of adverse effects can be increased when Telmisartan is combined with Fosinopril. Telmisartan may increase the hypotensive activities of Bupranolol. Bethanidine may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Nabilone is combined with Telmisartan. The risk or severity of adverse effects can be increased when Bisoprolol is combined with Telmisartan. The risk or severity of adverse effects can be increased when Pipamperone is combined with Telmisartan. Sildenafil may increase the antihypertensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Penbutolol. Telmisartan may increase the hypotensive activities of Cicletanine. The risk or severity of adverse effects can be increased when Bromocriptine is combined with Telmisartan. Methylphenidate may decrease the antihypertensive activities of Telmisartan. Iproclozide may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Dipyridamole. Caroxazone may increase the hypotensive activities of Telmisartan. Hydroflumethiazide may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Telmisartan. Telmisartan may increase the hypotensive activities of Lofexidine. Guanabenz may increase the hypotensive activities of Telmisartan. The serum concentration of Digitoxin can be increased when it is combined with Telmisartan. The risk or severity of adverse effects can be increased when Ropinirole is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Papaverine. Cyclothiazide may increase the hypotensive activities of Telmisartan. Travoprost may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Hydrochlorothiazide. The risk or severity of adverse effects can be increased when Telmisartan is combined with Lisofylline. Indoramin may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Paclitaxel is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Phenylbutazone. The risk or severity of adverse effects can be increased when Telmisartan is combined with Tenoxicam. Phenoxypropazine may increase the hypotensive activities of Telmisartan. The serum concentration of Digoxin can be increased when it is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Dapagliflozin. The risk or severity of adverse effects can be increased when Telmisartan is combined with Mesalazine. The risk or severity of adverse effects can be increased when Telmisartan is combined with Felbinac. Yohimbine may decrease the antihypertensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Andrographolide. The risk or severity of adverse effects can be increased when Olmesartan is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolate mofetil. The risk or severity of adverse effects can be increased when Morphine is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Irbesartan. The risk or severity of adverse effects can be increased when Bortezomib is combined with Telmisartan. Urapidil may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Mizoribine. The risk or severity of adverse effects can be increased when Amphotericin B is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole. The serum concentration of Colchicine can be increased when it is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Lumiracoxib. The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Telmisartan. Telmisartan may increase the hypotensive activities of Mibefradil. The risk or severity of adverse effects can be increased when Telmisartan is combined with Benzydamine. The serum concentration of Edoxaban can be increased when it is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Etodolac. Lercanidipine may increase the hypotensive activities of Telmisartan. Harmaline may increase the hypotensive activities of Telmisartan. Telmisartan may increase the hypotensive activities of Amifostine. The risk or severity of adverse effects can be increased when Arotinolol is combined with Telmisartan. The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Telmisartan. Bimatoprost may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Methyldopa. Telmisartan may increase the hypotensive activities of Talinolol. Telmisartan may increase the hypotensive activities of BQ-123. Telmisartan may increase the hypotensive activities of Ferulic acid. The risk or severity of adverse effects can be increased when Telmisartan is combined with SRT501. The risk or severity of adverse effects can be increased when Tolcapone is combined with Telmisartan. Methylene blue may increase the hypotensive activities of Telmisartan. Octamoxin may increase the hypotensive activities of Telmisartan. Cryptenamine may increase the hypotensive activities of Telmisartan. The risk or severity of adverse effects can be increased when Diltiazem is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Salicylamide. The risk or severity of adverse effects can be increased when Telmisartan is combined with Pimecrolimus. The risk or severity of adverse effects can be increased when Thioridazine is combined with Telmisartan. The risk or severity of adverse effects can be increased when Isoflurane is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Etanercept. The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Telmisartan. Telmisartan may increase the hypotensive activities of Oxprenolol. The risk or severity of adverse effects can be increased when Telmisartan is combined with Adapalene. The risk or severity of adverse effects can be increased when Nisoldipine is combined with Telmisartan. The risk or severity of adverse effects can be increased when Nicardipine is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Apremilast. Rasagiline may increase the hypotensive activities of Telmisartan. The serum concentration of Bosutinib can be increased when it is combined with Telmisartan. The risk or severity of adverse effects can be increased when Telmisartan is combined with Moexipril. Tinzaparin may increase the hyperkalemic activities of Telmisartan.